- Home
- CAI vs DVA Comparison
CAI vs DVA Comparison
Compare CAI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAI | DVA |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 10.1B |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | CAI | DVA |
|---|---|---|
| Price | $18.50 | $152.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $33.67 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 2.0M | 829.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $24.26 | $3.80 |
| Revenue Next Year | $22.60 | $3.04 |
| P/E Ratio | ★ N/A | $15.35 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $17.15 | $101.00 |
| 52 Week High | $42.50 | $159.42 |
Technical Indicators
Market Signals| Indicator | CAI | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 62.32 |
| Support Level | $17.15 | $133.97 |
| Resistance Level | $21.47 | $159.42 |
| Average True Range (ATR) | 1.27 | 4.29 |
| MACD | 0.13 | -1.27 |
| Stochastic Oscillator | 31.13 | 46.98 |
Price Performance
Historical ComparisonAbout CAI Caris Life Sciences Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.